Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cardiol Therapeutics Inc. T.CRDL

Alternate Symbol(s):  T.CRDL.W.A | CRDL

Cardiol Therapeutics’ lead product, CardiolRx™, is an oral pharmaceutical that is currently being evaluated in the Phase II multi-national ARCHER trial in patients presenting with acute myocarditis. Cardiol has received IND authorization from the FDA to conduct a clinical study to evaluate CardiolRx™ in a Phase II multi-center open-label pilot study in recurrent pericarditis. Cardiol is developing a subcutaneously administered drug formulation of cannabidiol intended for use in heart failure.


Recent & Breaking News (TSX:CRDL)

Cardiol Therapeutics says first patient enrolled in Phase 2 study of CardiolRx for Pericarditis

TheNewsWire January 17, 2023

Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Newsfile January 17, 2023

Why Investors Should Buy Into this Company Targeting Heart Diseases … Now

Jocelyn Aspa December 20, 2022

Cardiol Therapeutics begins Phase II study of CardiolRx for treatment of recurrent pericarditis

TheNewsWire December 16, 2022

Cardiol (TSX:CRDL) begins heart disease drug trials

Caroline Egan  December 12, 2022

Cardiol Therapeutics Commences Multi-Center Phase II Pilot Study of CardiolRx(TM) for the Treatment of Recurrent Pericarditis

Newsfile December 12, 2022

Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Newsfile November 14, 2022

CardiolRx study demonstrates ‘protective effects’ vs. acute pericarditis

Jeff Nielson November 9, 2022

Cardiol Therapeutics (TSX:CRDL) discovers protective effects of CardiolRX

Brieanna McCutcheon  November 7, 2022

Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis

Newsfile November 7, 2022

Cardiol Therapeutics Prioritizes Phase II Clinical Programs in Underserved Heart Diseases

Newsfile October 25, 2022

Cardiol Therapeutics (TSX: CRDL) announces CardiolRx pre-clinical study results

John Ballem  October 3, 2022

Cardiol Therapeutics Announces Pre-Clinical Study Results Demonstrating CardiolRx(TM) Inhibits and also Promotes Reversal of Mechanisms Leading to Cardiac Fibrosis

Newsfile October 3, 2022

Cardiol Therapeutics Announces Poster Presentation at The Annual Scientific Meeting of the Heart Failure Society of America

Newsfile September 28, 2022

60+ Companies to Present at the 2nd Annual MicroCap Rodeo - Windy City Roundup Conference on October 12th - 13th, 2022 in Chicago

Accesswire September 27, 2022

Is this company the next GW Pharma? Phase II study now underway

Jeff Nielson August 8, 2022

Cardiol Therapeutics (TSX:CRDL) reports first patient enrolled in Phase Il clinical trial for acute myocarditis treatment

Dave Jackson August 3, 2022

Cardiol Therapeutics Announces First Patient Enrolled in ARCHER, a Phase II Clinical Trial of CardiolRx(TM) for Treatment of Acute Myocarditis

Newsfile August 3, 2022

A medical play developing CBD-based treatments for cardiovascular diseases

Jon Brown July 13, 2022

Cardiol Therapeutics Reports Results of 2022 Annual General Meeting

Newsfile June 29, 2022